The BOOG 2013-08 trial evaluates whether SLNB can be safely omitted for patients with clinically T1-2N0 treated with ...

In the AXSANA/EUBREAST 3(R) study, researchers compared data about recurrence outcomes of more-invasive and less-invasive lymph node procedures.

A total of 333 patients were included in the study. The SLN could be identified in 328 out of 333 patients, calculating an identification rate of 98.5%. SLNs were positive for metastases in 128 out of ...

Background: The benefits of sentinel lymph node biopsy (SLNB) for breast cancer patients with histologically negative axillary nodes, in whom axillary lymph node dissection (ALND) is thereby avoided, ...

SAN ANTONIO -- Patients with early breast cancer who skipped axillary lymph node dissection (ALND) lived just as long as those who underwent sentinel lymph node biopsy (SLNB), the randomized INSEMA ...

Lymphatic mapping, a recent technique first developed for the management of melanoma, is based on the concept that information about the status of the entire lymphatic drainage from a tumor site could ...

SAN ANTONIO – Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional ...

SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for dermatology, hematology, and infectious & inflammatory diseases, announced today ...

EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results No ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from its prospective ...